Study on Preventing Rash and Diarrhea with Capivasertib in Breast Cancer Treatment

Inclusion Criteria

• Able to give informed consent and follow study requirements.
• Aged 18 years or older.
• Women (pre- or post-menopausal) and men with advanced breast cancer eligible for capivasertib and fulvestrant treatment.
• Cancer must be advanced or metastatic and not removable by surgery.
• Must have specific genetic changes in the cancer (PIK3CA/AKT1/PTEN alterations).
• Good overall health with a performance status of 0 or 1 and a life expectancy of at least 12 weeks.
• Must be able to swallow pills.
• Must agree to use effective contraception during and after the study if of childbearing potential.

Exclusion Criteria

• Have a type of cancer or condition that makes endocrine therapy unsuitable.
• Have had other cancers within the last five years, except for certain treated skin or cervical cancers.
• Have unresolved side effects from previous treatments.
• Have blood clotting issues or are on blood thinners that prevent certain injections.
• Have taken other cancer treatments recently without a proper break.
• Are using herbal or natural cancer treatments.
• Have had recent major surgery or radiation therapy.
• Are taking medications that interfere with study drugs.
• Have uncontrolled diabetes or high blood sugar.
• Have untreated or unstable brain or spinal cord cancer spread.
• Have inadequate blood cell counts or organ function.
• Have severe or uncontrolled health conditions, including infections like hepatitis or HIV.
• Have a history of lung disease or skin conditions that could worsen with capivasertib.
• Have allergies to study drugs or similar medications.
• Have digestive issues that affect medication absorption.
• Have mental health conditions that affect understanding or consent.